A PET Study Using C-DASB in Healthy Humans
John L Allinson & Ray Briggs
Vitor Harada of ICON presents the legal aspects when managing global studies, placing the emphasis on the importance of a risk assesment carried out on a country by country basis.
Following the withdrawl of a number of products from the market, drug safety leaders have taken part in an industry-wide survey to find out what is needed to ease compliance with new regulations.
Contract Research Organizations have followed different paths and models over the past decade. We asked several of the major CROs about the biggest changes and trends they've seen in their part of the business. Here’s what they had to say. —GYR
Stuart L. Cantor, PhD, Senior Scientist, and Kadriye Ciftci, PhD, Senior Director Drug Delivery, ICON Development Solutions